Glaukos Co. (NYSE:GKOS – Get Free Report) Director Gilbert H. Kliman sold 3,000 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $130.67, for a total transaction of $392,010.00. Following the sale, the director now directly owns 32,336 shares in the company, valued at approximately $4,225,345.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Glaukos Stock Performance
GKOS stock opened at $126.28 on Friday. The firm has a market cap of $6.94 billion, a price-to-earnings ratio of -43.85 and a beta of 1.03. Glaukos Co. has a twelve month low of $59.22 and a twelve month high of $136.60. The business’s fifty day simple moving average is $124.45 and its two-hundred day simple moving average is $109.86. The company has a quick ratio of 4.67, a current ratio of 5.48 and a debt-to-equity ratio of 0.19.
Glaukos (NYSE:GKOS – Get Free Report) last announced its quarterly earnings data on Wednesday, July 31st. The medical instruments supplier reported ($0.52) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.52). The company had revenue of $95.70 million for the quarter, compared to analysts’ expectations of $88.86 million. Glaukos had a negative return on equity of 22.51% and a negative net margin of 47.39%. Glaukos’s revenue was up 19.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.55) earnings per share. Analysts predict that Glaukos Co. will post -2.18 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Read Our Latest Research Report on Glaukos
Hedge Funds Weigh In On Glaukos
Institutional investors have recently made changes to their positions in the company. National Bank of Canada FI purchased a new stake in Glaukos in the fourth quarter worth about $46,000. Quadrant Capital Group LLC raised its holdings in shares of Glaukos by 54.8% in the 4th quarter. Quadrant Capital Group LLC now owns 929 shares of the medical instruments supplier’s stock valued at $74,000 after purchasing an additional 329 shares in the last quarter. Caldwell Sutter Capital Inc. lifted its position in shares of Glaukos by 5,860.0% in the 1st quarter. Caldwell Sutter Capital Inc. now owns 1,490 shares of the medical instruments supplier’s stock worth $140,000 after purchasing an additional 1,465 shares during the period. GAMMA Investing LLC boosted its stake in shares of Glaukos by 68.8% during the second quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier’s stock valued at $141,000 after purchasing an additional 486 shares in the last quarter. Finally, Fifth Third Wealth Advisors LLC purchased a new position in Glaukos during the second quarter valued at approximately $187,000. Hedge funds and other institutional investors own 99.04% of the company’s stock.
Glaukos Company Profile
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.
Recommended Stories
- Five stocks we like better than Glaukos
- Best Aerospace Stocks Investing
- Powering Your Portfolio: The Utility Sector’s Electrifying Surge
- What Are Growth Stocks and Investing in Them
- Adobe Stock Builds Long-Term Value: Consider Buying on the Dip
- Ride Out The Recession With These Dividend KingsĀ
- Albemarle Jumps as Lithium Stock Buying Frenzy Takes Off
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.